{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T16:20:51Z","timestamp":1788970851928,"version":"build-2803163510"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1097\/tp.0000000000001310","type":"journal-article","created":{"date-parts":[[2016,7,4]],"date-time":"2016-07-04T11:40:35Z","timestamp":1467632435000},"page":"1234-1241","source":"Crossref","is-referenced-by-count":32,"title":["Cost-Effectiveness of Antibody-Based Induction Therapy in Deceased Donor Kidney Transplantation in the United States"],"prefix":"10.1097","volume":"101","author":[{"given":"Zahra","family":"Gharibi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet U.S.","family":"Ayvaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hahsler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Giacoma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Gaston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bekir","family":"Tanriover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-17-20210211","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0039-6109(16)46445-5","article-title":"Cost issues in transplantation","volume":"74","author":"Eggers","year":"1994","journal-title":"Surg Clin North Am"},{"key":"R3-17-20210211","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1111\/j.1600-6143.2004.00565.x","article-title":"Cost-effectiveness of extending Medicare coverage of immunosuppressive medications to the life of a kidney transplant","volume":"4","author":"Yen","year":"2004","journal-title":"Am J Transplant"},{"key":"R5-17-20210211","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.2215\/CJN.09440912","article-title":"Future of Medicare immunosuppressive drug coverage for kidney transplant recipients in the United States","volume":"8","author":"Tanriover","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"issue":"Suppl 3","key":"R6-17-20210211","first-page":"S1","article-title":"Improving Global Outcomes Transplant Work G. KDIGO clinical practice guideline for the care of kidney transplant recipients.","volume":"9","author":"Kidney","year":"2009","journal-title":"Am J Transplant"},{"key":"R7-17-20210211","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/tri.12043","article-title":"Selection of induction therapy in kidney transplantation","volume":"26","author":"Hardinger","year":"2013","journal-title":"Transpl Int"},{"key":"R8-17-20210211","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.2215\/CJN.08710814","article-title":"Induction therapies in live donor kidney transplantation on tacrolimus and mycophenolate with or without steroid maintenance","volume":"10","author":"Tanriover","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"R9-17-20210211","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/ajt.12579","article-title":"OPTN\/SRTR 2012 Annual Data Report: kidney","volume":"14","author":"Matas","year":"2014","journal-title":"Am J Transplant"},{"key":"R10-17-20210211","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/00007890-200009150-00007","article-title":"Economic cost of expanded criteria donors in cadaveric renal transplantation: analysis of Medicare payments","volume":"70","author":"Whiting","year":"2000","journal-title":"Transplantation"},{"key":"R11-17-20210211","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1093\/ndt\/16.5.1028","article-title":"An economic and quality-of-life assessment of basiliximab vs antithymocyte globulin immunoprophylaxis in renal transplantation","volume":"16","author":"Polsky","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"R12-17-20210211","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.2215\/CJN.07540810","article-title":"Induction immunosuppressive therapy in the elderly kidney transplant recipient in the United States","volume":"6","author":"Gill","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"R13-17-20210211","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1056\/NEJMoa060068","article-title":"Thymoglobulin Induction Study G. Rabbit antithymocyte globulin versus basiliximab in renal transplantation","volume":"355","author":"Brennan","year":"2006","journal-title":"N Engl J Med"},{"key":"R14-17-20210211","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1523-1755.2005.00410.x","article-title":"Modifiable factors predicting patient survival in elderly kidney transplant recipients","volume":"68","author":"Cardinal","year":"2005","journal-title":"Kidney Int"},{"key":"R15-17-20210211","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1017\/S0266462399153157","article-title":"Uncertainty of incremental cost-effectiveness ratios. A comparison of Fieller and bootstrap confidence intervals","volume":"15","author":"Severens","year":"1999","journal-title":"Int J Technol Assess Health Care"},{"key":"R16-17-20210211","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1177\/0272989X0002000310","article-title":"Willingness to pay for a quality-adjusted life year: in search of a standard","volume":"20","author":"Hirth","year":"2000","journal-title":"Med Decis Making"},{"key":"R18-17-20210211","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1001\/archinte.163.14.1637","article-title":"What is the price of life and why doesn't it increase at the rate of inflation?","volume":"163","author":"Ubel","year":"2003","journal-title":"Arch Intern Med"},{"key":"R19-17-20210211","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1093\/ndt\/gfp174","article-title":"The cost-effectiveness of induction immunosuppression in kidney transplantation","volume":"24","author":"Morton","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"R20-17-20210211","first-page":"514","article-title":"Adding thymoglobuline to the conventional immunosuppressant regimen in kidney transplantation: a cost-benefit analysis","volume":"3","author":"Oliaei","year":"2012","journal-title":"Caspian J Intern Med"},{"key":"R21-17-20210211","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1097\/01.tp.0000442505.10490.20","article-title":"Outcome and cost analysis of induction immunosuppression with IL2Mab or ATG in DCD kidney transplants","volume":"97","author":"Popat","year":"2014","journal-title":"Transplantation"},{"key":"R22-17-20210211","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta9210","article-title":"Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study","volume":"9","author":"Woodroffe","year":"2005","journal-title":"Health Technol Assess"},{"key":"R23-17-20210211","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/01.TP.0000109643.32659.C4","article-title":"Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials","volume":"77","author":"Webster","year":"2004","journal-title":"Transplantation"},{"key":"R26-17-20210211","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1524-4733.2009.00660.x","article-title":"Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report\u2013Part II","volume":"13","author":"Garrison","year":"2010","journal-title":"Value Health"},{"key":"R27-17-20210211","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1009546","article-title":"Alemtuzumab induction in renal transplantation","volume":"364","author":"Hanaway","year":"2011","journal-title":"N Engl J Med"},{"key":"R30-17-20210211","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1432-2277.2006.00270.x","article-title":"Comparison of two dosages of thymoglobulin used as a short-course for induction in kidney transplantation","volume":"19","author":"Wong","year":"2006","journal-title":"Transpl Int"},{"key":"R31-17-20210211","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00007890-200202150-00025","article-title":"Short course induction immunosuppression with thymoglobulin for renal transplant recipients","volume":"73","author":"Agha","year":"2002","journal-title":"Transplantation"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000001310","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T07:24:36Z","timestamp":1620977076000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007890-201706000-00017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000001310","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]}}}